Taisho Pharmaceutical Holdings Co., Ltd.
TAIPY · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $42,781,389 | $32,683,129 | $27,647,449 | $28,236,183 |
| - Cash | $246,071,000 | $240,479,000 | $248,189,000 | $255,966,000 |
| + Debt | $8,886,000 | $5,842,000 | $5,770,000 | $2,590,000 |
| Enterprise Value | -$194,403,611 | -$201,953,871 | -$214,771,551 | -$225,139,817 |
| Revenue | $83,576,000 | $82,295,000 | $80,802,000 | $73,712,000 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Gross Profit | $46,480,000 | $46,915,000 | $48,280,000 | $41,490,000 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| EBITDA | $4,549,000 | $6,729,000 | $14,097,000 | $6,336,000 |
| % Margin | 5.4% | 8.2% | 17.4% | 8.6% |
| Net Income | $2,873,000 | $3,087,000 | $4,363,000 | -$1,902,000 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| % Growth | -6.9% | -29.3% | 329.1% | – |
| Operating Cash Flow | $21,194,000 | $14,578,000 | $13,904,000 | $13,432,000 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $21,194,000 | $14,578,000 | $13,904,000 | $13,432,000 |